Stock market news live updates: Stocks soar after back-to-back losing days – Yahoo Finance

U.S. stocks rallied Wednesday, led by gains in the technology sector, as strong earnings and economic data lifted sentiment on Wall Street after two straight sessions of losses.
The S&P 500 jumped 1.6%, and the Dow Jones Industrial Average gained 415 points, or roughly 1.3%. The tech-heavy Nasdaq Composite surged 2.6%.
Bonds also pushed forward after hawkish Fedspeak Tuesday, with the benchmark 10-year Treasury yield holding well above 2.7% and the 2-year yield near 3.1%.
Economic data out Wednesday that showed the U.S. services sector picked up in July helped at least temporarily relieve some concerns that a recession was unavoidable. The ISM Services PMI hit 56.7 percent last month in a surprise jump from June’s reading of 55.3 as supply chain issues appeared to ease.
St. Louis Federal Reserve President James Bullard also said he did not think the U.S. economy was in a recession in a televised interview with CNBC.
Robinhood (HOOD) shares closed up nearly 12%, one day after the brokerage said it would lay off nearly a quarter of its staff and reported its sixth straight quarterly loss.
Shares of CVS (CVS) gained 6.2% after the drugstore chain reported earnings that beat estimates and lifted its full-year guidance.
Starbucks (SBUX) shares rose 4.3% after the coffee house unveiled fiscal third quarter earnings late Tuesday that largely beat Wall Street estimates despite inflationary pressures, labor costs, unionization efforts and the search for a permanent CEO clouding the quarter.
Meanwhile, shares of AMD (AMD) slipped 1.2% following a warning by the chipmaker of a worse-than-expected third quarter late Tuesday.
As economic data shows signs of slowing and companies continue to dim their outlooks, analysts are making larger cuts than average to earnings per share estimates for S&P 500 companies for the third quarter. According to data from FactSet, Wall Street lowered its consensus bottom-up EPS estimate by 2.5% from June 30 to July 28. During the past five years – or 20 quarters – the average decline in the bottom-up EPS estimate during the first month of a quarter has been 1.3%.
In commodities markets, OPEC and its allies green lighted a small increase of about 100,000 barrels per day in oil production following calls by the U.S. and other major consumers for more supply. The move, while symbolic, is expected to have little impact on prices. Crude oil retreated from a daily high in the afternoon, with WTI (CL=F) just above $92 per barrel and Brent (BZ=F) at roughly $98.20.
Wednesday’s moves follow a down day on Wall Street that saw stocks close lower for a second consecutive session amid a high-stakes visit by House Speaker Nancy Pelosi to Taiwan that raised worries around U.S.-China relations.
On Tuesday, investors digested hawkish Fedspeak that suggested more interest rate hikes were underway the central bank’s efforts to curb inflation. San Francisco Fed President Mary Daly on Tuesday said policymakers were “resolute and completely united” in their objective of restoring price stability, and Chicago Fed President Charles Evans told reporters that officials were “at least a couple of reports away” from seeing enough improvement in inflation data to scale back on the pace of hiking rates.
Meanwhile, St. Louis Federal Reserve President James Bulllard said the U.S. Federal Reserve and the European Central Bank can still achieve a “relatively soft landing” as they tighten monetary conditions.
“I think the story for markets is still, ‘What’s happening with the Fed? What’s happening with tightening?’” Manulife Investment Management Global Macro Strategist Eric Theoret told Yahoo Finance Live on Tuesday. “When it comes to geopolitics, it’s not really driving market movement at the moment.”

Alexandra Semenova is a reporter for Yahoo Finance. Follow her on Twitter @alexandraandnyc
Click here for the latest stock market news and in-depth analysis, including events that move stocks
Read the latest financial and business news from Yahoo Finance
Download the Yahoo Finance app for Apple or Android
Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, LinkedIn, and YouTube
Related Quotes
Yahoo Finance Live anchors discuss reports that Apple has ditched plans to increase iPhone 14 production.
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.
Yahoo Finance Live anchors discuss Biogen stock performance on promising Alzheimer’s drug trial data.
Atlantic Equities analyst Hamilton Faber upgraded Netflix stock to overweight (buy) from neutral (hold), while simultaneously boosting his price target to $283, up from its former level of $211. The analyst cited the debut of Netflix's upcoming ad-supported tier, which he believes "could be extremely material" for the streaming service, the benefits of which haven't yet been accurately reflected in analysts' consensus estimates. Faber estimates that Netflix could generate average revenue per user (ARPU) of $26 per month from advertising, more than three times the rate of Disney's Hulu.
Yahoo Finance's Allie Garfinkle discusses news that Apple has asked suppliers to pull back production by up to 6 million units and what it signals about consumer demand ahead of the holiday season.
Shares of Nano-X Imaging (NASDAQ: NNOX), commonly called Nanox, soared on Wednesday after it revealed it's taken the next step toward commercializing its flagship medical device. As of 12:20 p.m. ET, Nanox stock was up 21%. Nanox had its initial public offering (IPO) in 2020, promising to disrupt the X-ray industry with its digital-3D imaging machines that will be cheaper for doctors to use.
Dividends can offer fat full-time income. But the math needs to work.
Yahoo Finance's Jared Blikre breaks down how stocks are trading after a huge move in bond yields after the Bank of England announced it would buy UK bonds.
In this article, we will be taking a look at the 10 companies that are buying back their stock in 2022. To skip our detailed analysis of these companies, you can go directly to see the 5 Companies that are Buying Back Their Stock in 2022. So far in 2022, we have seen a number of […]
In this article, we will discuss the 10 dividend paying stocks you should avoid according to Morgan Stanley’s quant screen. If you want to read about similar stocks, you can also take a look at 5 Dividend Paying Stocks You Should Avoid According to Morgan Stanley’s Quant Screen. Morgan Stanley’s Sherry Paul: “It’s a Buying […]
Things are bad. But at least ‘you can eat’ one of these assets.
Creating reliable streams of retirement income is one of the most important elements of a person's financial plan. A retirement industry giant says it now has a new way for retirees to meet this vital challenge. Fidelity Investments plans to … Continue reading → The post There's a New Way to Convert Your 401(k) into a Pension-like Stream of Income appeared first on SmartAsset Blog.
The benchmark S&P 500, which is typically viewed as the best barometer of stock market health, produced its worst first-half return in 52 years. As for the growth-driven Nasdaq Composite, an index largely responsible for pushing the stock market to new highs, it's lost about a third of its value. This puts both the S&P 500 and Nasdaq firmly in a bear market.
Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public of each common share and accompanying warrant is $4.25. Each common share will be sold in combination with an accompanying
If there is a silver lining to this year's downdraft in the stock market, it's providing investors with some great long-term investment opportunities. Three top dividend stocks that are down sharply and look like great buys right now are Brookfield Renewable (NYSE: BEPC)(NYSE: BEP), Digital Realty (NYSE: DLR), and Enbridge (NYSE: ENB).
Ocugen Inc. (NASDAQ: OCGN) of Malvern entered into an exclusive license agreement Wednesday with Washington University in St. Louis for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered Covid-19 vaccine in the United States, Europe, and Japan. It becomes the second Covid vaccine licensed by Ocugen, which continues to seek Food and Drug Administration approval for use of the other product, Covaxin, in the U.S. market. Under the financial terms of the deal, disclosed in documents filed with the Securities and Exchange commission, Ocugen will pay Washington University an initial license issuance fee of $1 million.
In this article, we discuss 11 best dividend aristocrat stocks to buy heading into recession. If you want to see more stocks in this selection, click 5 Best Dividend Aristocrat Stocks To Buy Heading Into Recession. Several of the world’s biggest economies face increasing recession risks as a result of the skyrocketing inflation and the […]
In this article, we discuss 10 high dividend stocks picked by billionaire Gabelli. You can skip our detailed analysis of GAMCO Investors’ investment philosophy and its performance, and go directly to read 5 High Dividend Stocks Picked by Billionaire Gabelli. Mario Gabelli built his reputation as one of Wall Street’s most successful investors when he […]
In this article, we discuss 10 most shorted stocks in the world. If you want to see more stocks on this list, click 5 Most Shorted Stocks in the World. Short squeezes have rapidly gained popularity in the last two years, when retail investors on Reddit gathered to initiate bullish positions in stocks that were […]
Blue Apron (APRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.


Leave a Comment